Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Carter Berezay who wrote (515)	7/5/1999 3:52:00 PM
From: daryl gordon	Read Replies (1) \| Respond to of 792

Gentlemen: I called my broker at Yorkton today to see why MBI wasn't at least receiving the gains that have been recorded on the TSE in general in the last month or so. I got the same old tired rhetoric that we have all likely heard, only this time the guy I spoke with threw out the number of $100 + per share within the next 2 years and he also quoted some other analyst who predicts $300 per share within 10 years based on the market value projected for the new synthetic antibiotics. If only 10% of this happens we should still be in good shape investment wise, but I would sure like to see some glowing reports from someone other than Yorkton. Any suggestions on where to look? Thanks Daryl Gordon dsgordon@telusplanet.net

To: Carter Berezay who wrote (515)	7/5/1999 8:19:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 792

Any news from Micrologix regarding their relationship with PENCE? I noticed an article, in the June/99 issue of the U of A Faculty of Medicine and Dentistry News, titled Fighting Mutating Bacteria with New Weapons of Destruction. "...That increasingly urgent fight against multi-drug resistant strains of bacteria took centre stage at the 40th annual National Student Research Forum held earlier this spring at the University of Texas, when University of Alberta MD student Jeffery Man captured the top prize in the biochemistry/molecular biology category. Man spent the previous summer working under the tutelage of Protein Engineering Networks of Centres of Excellence researchers Robert Hodges and Les Kondejewski. That work focussed on designing drugs to which microorganisms will be likely to develop resistance. The researchers are using a naturally occurring, antimicrobial peptide, Gramicidin S, to attack the cell membranes of bacteria. Their goal is to devellop an effective way of attacking the bacteria's cell membrane, to destroy the integrity of the cell, and yet leave the healthy eukaryotic cells untouched. "We now have something that works in a test tube," says Dr. Kondehewski. "It kills bugs and not blood cells. Our next step is to test these compounds on other cell types and conduct research in vivo." The team has developed highly active antimicrobial peptides with high specificity for bacteria over eukaryotic cells. Man's student work, which was funded by a summer studentship from the Alberta Heritage Foundation for Medical REsearch, is part of a much broader scope of work that began in PENCE on a relatively small scale. That effort now encompasses a host of researchers and is backed by Micrologix Biotech Inc..."